You are viewing the site in preview mode

Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas

Fig. 6

Transcription factor IRF1 substitutes for the loss of IRF2. A Same experimental design as 5C and 5D except, IRF1 mRNA expression was analyzed by qPCR. B-E EV, IRF1KO, IRF2KO and DKO (IRF1+IRF2KO) B16F0 cells were stimulated with IFNα in vitro and analyzed by: B Western blot for IRF1 or ß-actin; C. qPCR expression for MHC I pathway components (n=2/group). D & E Surface MHC I levels after 0 or 100 ng/ml IFNα treatment for 24 h (n=2/group)

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us